<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02699684</url>
  </required_header>
  <id_info>
    <org_study_id>CLE270-P001</org_study_id>
    <nct_id>NCT02699684</nct_id>
  </id_info>
  <brief_title>Comparison of Lotrafilcon B Lenses With Different Packaging Solutions</brief_title>
  <official_title>One Month Clinical Comparison of Two Lotrafilcon B Spherical Lenses With Different Packaging Solutions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate AIR OPTIX® plus HYDRAGLYDE® (AOHG) contact lenses
      compared to AIR OPTIX® AQUA (AOA) contact lenses in overall lens fit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects must not wear any contact lenses prior to the visit on Day 1 (Insertion) for Period
      1 or Day 1 (Insertion) for Period 2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 12, 2016</start_date>
  <completion_date type="Actual">October 20, 2016</completion_date>
  <primary_completion_date type="Actual">October 20, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Satisfying the &quot;no Re-fit&quot; Criteria in Both Eyes</measure>
    <time_frame>Day 30, each product</time_frame>
    <description>Overall lens fit was graded by the Investigator on a 5-point scale: -2 (unacceptably tight); -1 (acceptably tight); 0 (optimal fit); +1 (acceptable loose); +2 (unacceptable loose). 'No re-fit' criteria was satisfied if an acceptable or optimal overall lens fit, that was also within one grade of the habitual lens fit value, was achieved.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Ex Vivo Total Cholesterol Uptake After 30 Days of Wear</measure>
    <time_frame>Day 30, each product</time_frame>
    <description>The contact lens was removed from the eye. Cholesterol deposits were extracted and measured in micrograms (μg) per lens. Lower deposits indicate increased lens performance. Only one eye (right eye) contributed to the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Insertion in Minimum Protected Area (MPA)</measure>
    <time_frame>Hour 0 (Lens Insertion) to Hour 12 on Day 1</time_frame>
    <description>MPA (the minimum area of the contact lens surface (expressed in %) protected by the tear film between two natural blinks) was assessed by the Investigator during the interblink period using the Tearscope® lighting system. Higher values indicate a more stable tear film in front of the lens. This Outcome Measure was pre-specified for AOHG only. Both eyes contributed to the analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Refractive Error</condition>
  <arm_group>
    <arm_group_label>AOHG, then AOA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Lotrafilcon B contact lenses with EOBO-41 worn first, followed by lotrafilcon B contact lenses worn second. Both products worn bilaterally (in both eyes) for 30 days and removed nightly for care using a hydrogen peroxide-based lens care solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AOA, then AOHG</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Lotrafilcon B contact lenses worn first, followed by lotrafilcon B contact lenses with EOBO-41 worn second. Both products worn bilaterally for 30 days and removed nightly for care using a hydrogen peroxide-based lens care solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lotrafilcon B contact lenses with EOBO-41</intervention_name>
    <description>Lotrafilcon B contact lenses packaged with copolymer 845 and EOBO-41</description>
    <arm_group_label>AOHG, then AOA</arm_group_label>
    <arm_group_label>AOA, then AOHG</arm_group_label>
    <other_name>AIR OPTIX® plus HYDRAGLYDE®</other_name>
    <other_name>AOHG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lotrafilcon B contact lenses</intervention_name>
    <description>Lotrafilcon B contact lenses packaged with copolymer 845</description>
    <arm_group_label>AOHG, then AOA</arm_group_label>
    <arm_group_label>AOA, then AOHG</arm_group_label>
    <other_name>AIR OPTIX® AQUA</other_name>
    <other_name>AOA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydrogen peroxide-based lens care solution</intervention_name>
    <description>Commercially-available hydrogen peroxide-based lens care solution for cleaning, disinfecting, and storing silicone hydrogel soft contact lenses</description>
    <arm_group_label>AOHG, then AOA</arm_group_label>
    <arm_group_label>AOA, then AOHG</arm_group_label>
    <other_name>AOSEPT® PLUS</other_name>
    <other_name>CLEAR CARE® PLUS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Saline solution for rinsing contact lenses</intervention_name>
    <description>Commercially-available saline solution used as needed</description>
    <arm_group_label>AOHG, then AOA</arm_group_label>
    <arm_group_label>AOA, then AOHG</arm_group_label>
    <other_name>Minims®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Saline solution for rinsing contact lens case</intervention_name>
    <description>Commercially-available solution used as needed</description>
    <arm_group_label>AOHG, then AOA</arm_group_label>
    <arm_group_label>AOA, then AOHG</arm_group_label>
    <other_name>LENS PLUS® OCUPURE™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must sign Informed Consent Document;

          -  Manifest cylinder less than or equal to 0.75 Diopter (D) in each eye;

          -  Successful current wearer (during the past 2 months for a minimum of 5 days per week
             and 8 hours per day) of AOA contact lenses within the protocol-specified power range;

          -  Willing to answer text messages on a daily basis during the study;

          -  Willing to discontinue artificial tears and rewetting drops on the days of study
             visits;

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Habitual lens wear in an extended wear modality (routinely sleeping in lenses
             overnight for 1 night per week);

          -  Any anterior segment infection, inflammation, disease or abnormality that
             contraindicates contact lens wear (within 7 days of enrollment, or current);

          -  History of herpetic keratitis, corneal surgery or irregular cornea;

          -  Any use of systemic or ocular medications for which contact lens wear could be
             contraindicated;

          -  Monocular (only 1 eye with functional vision) or fit with only 1 lens;

          -  Pregnant or lactating;

          -  Participation in any clinical study within 30 days of Visit 1;

          -  Other protocol-specified exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Manager, EMEA</last_name>
    <role>Study Director</role>
    <affiliation>Alcon, A Novartis Division</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2016</study_first_submitted>
  <study_first_submitted_qc>March 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2016</study_first_posted>
  <results_first_submitted>August 7, 2017</results_first_submitted>
  <results_first_submitted_qc>August 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 7, 2017</results_first_posted>
  <last_update_submitted>August 7, 2017</last_update_submitted>
  <last_update_submitted_qc>August 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Hydrogen Peroxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 1 study center located in the United Kingdom (UK).</recruitment_details>
      <pre_assignment_details>Of the 82 enrolled, 6 subjects were exited as screen failures prior to randomization. One subject withdrew consent after randomization, but before exposure to product. This reporting group includes all randomized and exposed subjects (75).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AOHG, Then AOA</title>
          <description>Lotrafilcon B contact lenses with EOBO-41 worn first, followed by lotrafilcon B contact lenses worn second. Both products worn bilaterally (in both eyes) for 30 days and removed nightly for care using a hydrogen peroxide-based lens care solution.</description>
        </group>
        <group group_id="P2">
          <title>AOA, Then AOHG</title>
          <description>Lotrafilcon B contact lenses worn first, followed by lotrafilcon B contact lenses with EOBO-41 worn second. Both products worn bilaterally for 30 days and removed nightly for care using a hydrogen peroxide-based lens care solution.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1, First 30 Days of Wear</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2, Second 30 Days of Wear</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This analysis population includes all randomized and exposed subjects (Full Analysis Set).</population>
      <group_list>
        <group group_id="B1">
          <title>Overall</title>
          <description>Lotrafilcon B contact lenses with EOBO-41 and lotrafilcon B contact lenses worn bilaterally during Period 1 and Period 2 in a crossover assignment, as randomized.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.7" spread="10.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Satisfying the “no Re-fit” Criteria in Both Eyes</title>
        <description>Overall lens fit was graded by the Investigator on a 5-point scale: -2 (unacceptably tight); -1 (acceptably tight); 0 (optimal fit); +1 (acceptable loose); +2 (unacceptable loose). 'No re-fit' criteria was satisfied if an acceptable or optimal overall lens fit, that was also within one grade of the habitual lens fit value, was achieved.</description>
        <time_frame>Day 30, each product</time_frame>
        <population>Full Analysis Set. Number Analyzed is the number of subjects with non-missing response.</population>
        <group_list>
          <group group_id="O1">
            <title>AOHG Contact Lenses</title>
            <description>Lotrafilcon B contact lenses with EOBO-41 worn bilaterally for 30 days in Period 1 or 2, as randomized</description>
          </group>
          <group group_id="O2">
            <title>AOA Contact Lenses</title>
            <description>Lotrafilcon B contact lenses worn bilaterally for 30 days in Period 1 or 2, as randomized</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Satisfying the “no Re-fit” Criteria in Both Eyes</title>
          <description>Overall lens fit was graded by the Investigator on a 5-point scale: -2 (unacceptably tight); -1 (acceptably tight); 0 (optimal fit); +1 (acceptable loose); +2 (unacceptable loose). 'No re-fit' criteria was satisfied if an acceptable or optimal overall lens fit, that was also within one grade of the habitual lens fit value, was achieved.</description>
          <population>Full Analysis Set. Number Analyzed is the number of subjects with non-missing response.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3"/>
                    <measurement group_id="O2" value="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Ex Vivo Total Cholesterol Uptake After 30 Days of Wear</title>
        <description>The contact lens was removed from the eye. Cholesterol deposits were extracted and measured in micrograms (μg) per lens. Lower deposits indicate increased lens performance. Only one eye (right eye) contributed to the analysis.</description>
        <time_frame>Day 30, each product</time_frame>
        <population>Full Analysis Set. Only the right (OD) lenses were collected from a subset of subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>AOHG Contact Lenses</title>
            <description>Lotrafilcon B contact lenses with EOBO-41 worn bilaterally for 30 days in Period 1 or 2, as randomized</description>
          </group>
          <group group_id="O2">
            <title>AOA Contact Lenses</title>
            <description>Lotrafilcon B contact lenses worn bilaterally for 30 days in Period 1 or 2, as randomized</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Ex Vivo Total Cholesterol Uptake After 30 Days of Wear</title>
          <description>The contact lens was removed from the eye. Cholesterol deposits were extracted and measured in micrograms (μg) per lens. Lower deposits indicate increased lens performance. Only one eye (right eye) contributed to the analysis.</description>
          <population>Full Analysis Set. Only the right (OD) lenses were collected from a subset of subjects.</population>
          <units>μg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.231"/>
                    <measurement group_id="O2" value="0.27" spread="0.173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Insertion in Minimum Protected Area (MPA)</title>
        <description>MPA (the minimum area of the contact lens surface (expressed in %) protected by the tear film between two natural blinks) was assessed by the Investigator during the interblink period using the Tearscope® lighting system. Higher values indicate a more stable tear film in front of the lens. This Outcome Measure was pre-specified for AOHG only. Both eyes contributed to the analysis.</description>
        <time_frame>Hour 0 (Lens Insertion) to Hour 12 on Day 1</time_frame>
        <population>Full Analysis Set. Number Analyzed is the number of eyes with non-missing response.</population>
        <group_list>
          <group group_id="O1">
            <title>AOHG Contact Lenses</title>
            <description>Lotrafilcon B contact lenses with EOBO-41 worn bilaterally for 30 days in Period 1 or 2, as randomized</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Insertion in Minimum Protected Area (MPA)</title>
          <description>MPA (the minimum area of the contact lens surface (expressed in %) protected by the tear film between two natural blinks) was assessed by the Investigator during the interblink period using the Tearscope® lighting system. Higher values indicate a more stable tear film in front of the lens. This Outcome Measure was pre-specified for AOHG only. Both eyes contributed to the analysis.</description>
          <population>Full Analysis Set. Number Analyzed is the number of eyes with non-missing response.</population>
          <units>percentage of contact lens surface area</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Insertion (Hour 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.839" spread="24.775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Insertion (Hour 12 - Hour 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.396" spread="23.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected from time of consent for the duration of a subject’s participation in the study (up to 74 days). AEs are reported as pre-treatment and treatment-emergent.</time_frame>
      <desc>An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users or other persons, whether or not related to the medical device.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pretreatment</title>
          <description>All subjects who consented to participate in the study prior to initiation of study treatment</description>
        </group>
        <group group_id="E2">
          <title>AOHG Contact Lenses</title>
          <description>All subjects exposed to AOHG contact lenses</description>
        </group>
        <group group_id="E3">
          <title>AOA Contact Lenses</title>
          <description>All subjects exposed to AOA contact lenses</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Food Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. Global Brand Medical Affairs Lead, GCRA</name_or_title>
      <organization>Alcon, A Novartis Division</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

